Drug intelligence / Profile preview

QLS2309

Development stage: Phase 1
Lead developer: Qilu Pharmaceutical
Administration: Intravenous Infusion

Overview

QLS2309 is an investigational drug developed by Qilu Pharmaceutical Co., Ltd. It is administered as an injection and is being evaluated in a Phase I clinical study for its tolerability, safety, pharmacokinetics, and preliminary antitumor activity in patients with CD70+ relapsed/refractory hematologic malignancies.

Targets

CD70 (Cluster of Differentiation 70)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on QLS2309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLS2309.

Explore the full profile